Floatz logo

Epirubicin

Metastatic Prostate Small Cell Carcinoma

Rahul AggarwalPhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Metastatic Prostate Small Cell Carcinoma cohort.

Asset / SponsorPhaseRating
CABAZITAXEL
M.D. Anderson Cancer Center
Phase 2B
Pembrolizumab
Rahul Aggarwal
Phase 2B
Cyclophosphamide
Fred Hutchinson Cancer Center
Phase 2B
Bet Bromodomain Inhibitor Zen-3694
Rahul Aggarwal
Phase 2CCC
Enzalutamide
Rahul Aggarwal
Phase 2CCC
Niraparib
M.D. Anderson Cancer Center
Phase 2CCC
Cetrelimab
Rahul Aggarwal
Phase 2CCC

Same molecule, other indications

Epirubicin is also rated in:

Recurrent Breast CarcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
Lung Non-Small Cell Squamous CarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
Advanced/Metastatic Gastroesophageal AdenocarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →